NEWSROOM

Get the latest Terumo Aortic news featuring our tailored thoracic,
thoracoabdominal and abdominal devices.

TERUMO AORTIC ANNOUNCES US FDA BREAKTHROUGH DEVICE DESIGNATION FOR RELAYBRANCH

Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the RelayBranch Thoracic Stent-Graft System. The RelayBranch Thoracic Stent-Graft System is implanted in patients with thoracic aortic arch pathologies requiring treatment that includes coverage of the innominate and left common carotid arteries. The purpose of the FDA’s

TERUMO AORTIC ANNOUNCES FIRST COMMERCIAL IMPLANT OF “UPON REQUEST” RELAYPRO ENDOVASCULAR DEVICE IN THE UNITED STATES

Terumo Aortic today announced the first commercial implant of a RelayPro Thoracic Stent-Graft System developed through its “Upon Request” program in the United States. With the “Upon Request” program, there are approximately 2000 stent-graft configurations approved by the US Food and Drug Administration (FDA) which allow physicians significantly more solutions to better fit the anatomical

TERUMO AORTIC ANNOUNCES PMDA APPROVAL FOR RELAYPRO ENDOVASCULAR DEVICE IN JAPAN

Terumo Aortic today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval of the RelayPro Thoracic Stent-Graft System for sale in Japan for the treatment of patients with thoracic aortic aneurysms (TAA). RelayPro is a low profile, next generation thoracic stent-graft device designed to expand the treatment of thoracic endovascular aortic



For more updates on Terumo Aortic, follow us on Twitter or LinkedIn.

MEDIA ENQUIRIES

Please reach out to our media relations contact for
press enquiries about our innovative solutions.


Carrie White
Head, Global Marketing Communications
+44 (0) 141 812 5555